

1 **Title page**

2 **Impacts of Radiotherapy for Gynaecological Cancer on Social,**
3 **Personal and Sexual Lives: A Qualitative Analysis of Patient**
4 **Narratives**

5 Lisa Anne Ashmore^{1*}, Hilary Stewart¹, Mette Kragh-Furbo¹, Daniel Hutton³, Lorraine Salisbury⁴,
6 Corinne Singleton¹, Vicky Singleton²

7 * corresponding author, l.ashmore@lancaster.ac.uk

8 ¹ Lancaster Medical School, Lancaster University, Sir John Fisher Drive, Bailrigg, Lancaster, LA1
9 4YW, United Kingdom

10 ² Department of Sociology, Bowland College, Lancaster University, Lancaster, LA1 4YT, United
11 Kingdom

12 ³ North West Radiotherapy Operational Delivery Network, Christie Hospitals NHS Foundation
13 Trust, Manchester, United Kingdom

14 ⁴ The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral,
15 CH63 4JY, United Kingdom

16

46 **Funding:** The research was funded by North West Cancer Research CR1201

47 **Keywords:** Radiotherapy; Gynaecological Cancer; Neoplasm; Narratives; Qualitative Research;

48 Patient Experience; Patient Care.

49

50 **Introduction**

51 In 2022 approximately 19,000 new diagnoses of gynaecological cancer were recorded in England,
52 accounting for around 12% of all female cancer diagnoses, and approximately 10% of cancer deaths
53 (1,2). Radiotherapy is utilised in approximately 40% of uterine, cervical, vaginal and vulval cancers,
54 with 10 year survival rates ranging from 58% - 71.7% (3). Despite improvements in survival, patients
55 undergoing gynae-radiotherapy face significant physical and psychosocial burdens (4–6). Treatment
56 protocols require strict personal hygiene regimens and preparation (e.g. maintaining a full bladder
57 and empty bowel), which cause considerable stress and inconvenience (7).

58 Research on patient experiences of radiotherapy for other cancers, such as breast (8) and head and
59 neck (9), has highlighted distress related to body image, feelings of helplessness, social isolation,
60 insufficient social support, unclear communication of risk, and self-criticism. Frequently, these non-
61 therapeutic effects are framed as ‘necessary suffering’ (10,11), which obscures opportunities to
62 understand and improve supportive care.

63 Quality of life for patients receiving radiotherapy for gynaecological cancers is reported to
64 significantly worsen as patients experience non-therapeutic effects of treatment, improving once
65 transient effects subside (12). However, long-term effects affecting quality of life are reported in
66 approximately 20-50% of patients who have undergone radiotherapy for a gynaecological cancer
67 (13). These include psychosocial and physical symptoms such as depression, anxiety, fear of dying,
68 fatigue, symptoms of the urinary and gastrointestinal tract (pain, bladder dysfunction and irritation,
69 inflammation of the rectum), lymphoedema, narrowing of the vaginal opening, weakening of the
70 vaginal walls, infertility, and premature menopause (4–6,14). Persistent gastrointestinal and pelvic
71 symptoms lasting three months or more is described as pelvic radiation disease (PRD), a condition
72 whose incidence is rising in line with increasing numbers of pelvic cancer patients being diagnosed
73 and successfully treated (15). Yet, the lack of robust measurement tools and patient reported
74 outcome data hampers accurate quantification of PRD prevalence and impact (16).

75 Fatigue, reported by 60-90% of cancer patients during treatment and persisting in 30% for months
76 after, is especially prevalent in those treated for cervical and ovarian cancers (12,17,18). This
77 distressing symptom interferes with an individual's ability to carry out daily activities (17), negatively
78 affecting mood and quality of life (18) and it can lead to anxiety and depression (12). During
79 radiotherapy treatment, the skin on the genitals and pelvic region can appear and feel burned (with
80 dry and moist desquamation) for more than six months following treatment. Beyond physiological
81 effects, research indicates that treatment also considerably affects sexual health, body image,
82 gender role performance (femininity), sexual function and fertility (19).

83 While technological advances in radiotherapy have rapidly improved precision and efficacy,
84 supportive care addressing physiological and psychological consequences has not kept pace (20).
85 This technical emphasis often sidelines patient voices, minimising attention to lived experiences and
86 concerns relating to sexual wellbeing, mental health and overall quality of life (14). Furthermore,
87 reductions in the time and settings available for supportive care hinder meaningful dialogue, often
88 limiting discussions to more generalised medical terms that fail to capture patients' sexual interests
89 and preferences (21).

90 Experiences of care are influenced by complex intersectional factors including age, race and
91 ethnicity, dis/ability, gender and sexuality. In part due to the technological drive in radiotherapy,
92 patient voices have been silenced in favour of technoscientific knowledge reflective of the medical
93 and clinical gaze (20,22–25). The paucity of resources and knowledge about non-therapeutic effects
94 restricts patients from being able to make sense of and respond to their experiences (26) and
95 negatively affects the quality of interactions between radiotherapy staff and their patients (27).
96 Embedded in dominant 'cure agendas', a techno-scientific gaze often fails to fully address patient
97 care needs of individuals living with life-changing treatment effects (28). Structural gaps in
98 understanding difference of experience and reaction to radiation treatment leads to paucity of care
99 for many (29).

100 Although a significant amount of research exists on patients' experiences of cancer broadly, much of
101 this work does not specifically address the unique demands of radiotherapy. Research which
102 positions living with and beyond cancer as a form of 'biographical disruption' (30,31); as 'existential'
103 crisis (32,33); as stigmatising (34–36); marginalising (37); as a 'suffering' (10,38) has tended to focus
104 on chemotherapy burdens or diagnostic impacts. Whilst prehabilitation interventions to address
105 multifaceted challenges faced by those undergoing gynaecological radiotherapy (39,40), significant
106 gaps remain in understanding lived experiences of communication, emotional wellbeing, intimacy,
107 and social support (40), areas explored in the present study.

108 Recent research on brachytherapy highlights wide variation in patient experiences, from minimal
109 discomfort to severe pain, psychological distress, and prolonged aftereffects, often linked to
110 treatment duration, applicator type, and care quality (41). Related work on chronic bowel symptoms
111 after pelvic radiotherapy demonstrates similar patterns: participants reported loss of control,
112 embarrassment, anxiety, and social withdrawal, leading to impacts on intimacy, work, and broader
113 quality of life (42). Our study differs by adopting a feminist, narrative approach, centring patient
114 voices to explore how gynaecological radiotherapy intersects with identity, agency, and everyday

115 life. This perspective provides a foundation for activist research that demands transformation of the
116 policies, practices, and cultural attitudes that limit patient wellbeing.

117 Feminist approaches to health have argued that silences and lack of understanding of diversity of
118 experience are created because a patriarchal biomedical approach dominates care practices (43–45).
119 Feminist approaches hence focus on collating and sharing embodied experiences of health and
120 illness and adopt a holistic approach that attends to social and emotional aspects of health and
121 illness alongside biological. The aim is to validate diversity of experiences and to empower patients
122 to draw upon their embodied experience as valuable knowledge. This project adopts such a
123 transformative lens to critically engage with radiotherapy practices and assumptions regarding
124 patients' priorities, needs and experiences.

125 Feminist work on breast cancer has critiqued the lack of understanding of patient experiences (46),
126 the relentless focus on positivity, and the 'pinkification' of the disease that silences suffering (47,48);
127 alongside issues of commercialisation, care resources, environmental causes and overly invasive
128 treatments (48–50). In contrast, gynaecological cancers have received comparatively less attention.
129 Consequently, the (very different) experiences related to diagnosis and treatment of a
130 gynaecological cancer remain poorly understood, partly due to cultural taboos around talking about
131 sexual organs and sexuality (51–53). The breast cancer literature provides a vital historical and
132 feminist framework for understanding these disparities and the need for greater attention to gynae-
133 specific issues.

134 This study addresses that gap by exploring how radiotherapy impacts on social, personal and sexual
135 lives. It gathered narratives of radiotherapy encounters, creating opportunities for patients to share
136 their lived, real-time experiences, revealing the emotional depths, complexities and subtleties of
137 illness and treatment that are often silenced, ignored, or 'othered' in decision-making processes. By
138 focussing on these affective forces, the study highlights what truly matters to patients, centring their
139 values and meanings in navigating life with cancer, and care (54).

140 Personal narratives uniquely 'illustrate and illuminate' the complexities of embodied (55) and
141 transient experiences (55), through emphatic witnessing (56) of voices that are traditionally silenced
142 or overlooked. By weaving together biographical threads such as resilience, forbearance and
143 humour, the narrative approach affords the 'assembly of life episodes' (57). Widely used in chronic
144 illness research (58–60), narrative approaches have been effective in transforming private suffering
145 into public awareness and shifting policy (61). To our knowledge, no previous study has collected
146 patient narrative accounts of radiotherapy for gynaecological cancer. This project harnesses

147 storytelling as a powerful form of activism, challenging existing norms and advocating for more
148 patient-centred supportive care.

149 **Methods**

150 Following participatory research method traditions, a workshop was held at the start of the project
151 to co-create a research protocol that was acceptable, relevant, and inclusive (62). Attendees (n=13)
152 at the workshop included people with lived experience of cancer (n=2), third sector organisations
153 including LGBTQI+ support officer from a cancer charity (n=3), radiotherapy and research
154 practitioners (n=4), and members of the research team (n=4). One of the people with lived
155 experience of cancer had lived experience of gynaecological cancer. As a result of the co-creation
156 event the timing, project requirements and support materials needed were developed. Further
157 details of the workshop are included in Appendix 1. This co-design process shaped not only the study
158 protocol but also the recruitment materials, consent process, participant guide and flexible narrative
159 collection methods, ensuring that participants could contribute in ways that felt safe and accessible
160 to them.

161 Two recruitment routes were used to gather two data sets: (1) contemporaneous narratives during
162 radiotherapy treatment and (2) reflections on experiences of radiotherapy treatment. These are
163 explained in detail in turn. The rationale for collecting two data sets was that recruitment for the
164 contemporaneous study was significantly disrupted by the suspension of research activity in
165 secondary care during the COVID-19 pandemic. To address this, a second, online project was
166 developed to capture retrospective reflections from a wider pool of participants.

167 (1) Contemporaneous narratives during radiotherapy treatment (Contemporaneous Project)

168 The contemporaneous study was undertaken in a large National Health Service (NHS) tertiary cancer
169 centre in the North West of England, providing on-site radiotherapy and specialist gynaecological
170 oncology services to a population of 2.4million. Patients were identified from the hospital medical
171 systems by the Clinical Effectiveness Team (CET) on a weekly basis. Personal information screened
172 for included: name, date of birth, contact details, cancer diagnosis, and whether they were
173 scheduled to receive radiotherapy treatment. The CET highlighted potential participants to a
174 research radiographer and lead research nurse. Potentially eligible participants were first
175 approached by the lead research nurse/research radiographer who discussed the study with them
176 and offered them the Participant Information Sheets. At this time, patients could choose to consent
177 to take part in the study or they may opt to take more time to consider participation and consent at
178 a later stage. For reasons of participant confidentiality, the name of the hospital is not disclosed.

179 Once a patient provided written consent to take part in the study, the patient contact details, and
180 demographic information was shared with the research team at Lancaster University. Following
181 consent, a researcher from the University contacted participants to follow up and provide further
182 information about participation in the study, including sending a participant guide (included in
183 supplementary materials).

184 Recruitment was aimed at individuals referred for radical or palliative radiotherapy for any
185 gynaecological cancer representing a range of experiences.

186 Recruitment was set to continue until at least one journal entry had been collected from 30 patients.
187 However, due to the suspension of research studies at the hospital site during the COVID-19
188 pandemic, the period for recruitment was limited. A second, online project was developed that
189 recruited patients who had treatment for radiotherapy at any point in the past, from any
190 radiotherapy centre in the UK.

191 Inclusion Criteria:

- 192 • Diagnosis of gynaecological cancer
- 193 • Scheduled to receive radiotherapy treatment for gynaecological cancer (including
194 brachytherapy, adjuvant and neo-adjuvant chemotherapy)
- 195 • Capacity to independently consent to involvement in the study
- 196 • Able to demonstrate understanding and respond to verbal and written material in English

197 Exclusion Criteria:

- 198 • Under 18 years of age
- 199 • Unable to communicate in spoken and written English

200

201 (2) Reflections on experiences of radiotherapy treatment (Online Project)

202 Participants were recruited to the online project through advertising on social media sites and via
203 various cancer charities. Potential participants were asked to contact the research team by phone or
204 email, following which they were provided with a digital participant information sheet and digital
205 consent form provided online. To register to take part in the study, participants were required to
206 complete the consent form, at which point, a researcher from Lancaster University contacted them
207 by phone/email to provide further information about participation in the study. A participant guide
208 was also emailed to participants following consent.

209 The number of journal entries submitted differed for each patient, based on individuals'
210 experiences, and covered the period from start of radiotherapy to 25 years post treatment. No
211 upper limit was set for time since treatment, as the study aimed to capture diverse experiential
212 accounts of gynae-radiotherapy rather than generate temporally bounded or statistically
213 transferable findings. Some patients who consented did not submit a journal entry. If a patient did
214 not submit a journal entry within the first two months of taking part in the study, a reminder was
215 sent. If there was no response to the reminder, the patient was removed from the study. A
216 safeguarding check of all narratives was performed by the research team and, should a concern have
217 been identified, the patient's nominated clinician (provided at consent) would have been contacted.
218 No concerns were identified.

219 Inclusion Criteria:

- 220 • Diagnosis of gynaecological cancer
- 221 • Had received radiotherapy treatment, for gynaecological cancer in the United Kingdom
222 (including brachytherapy, adjuvant and neo-adjuvant chemotherapy) or cared for someone
223 who had received radiotherapy
- 224 • Capacity to independently consent to involvement in the study
- 225 • Able to demonstrate understanding and respond to verbal and written material in English

226 Exclusion Criteria:

- 227 • Under 18 years of age
- 228 • Unable to communicate in spoken and written English

229 Ethical approval for the contemporaneous project was granted by the East of Scotland Research
230 Ethics Committee (20/ES/0008). Approval for the online project was granted by the Lancaster
231 University Faculty of Health and Medicine Research Ethics Committee (FHMREC19086). Both studies
232 aimed to recruit patients until 30 narratives for each were received, however we anticipated that
233 the contemporaneous study would not reach that number due to COVID-19 pandemic disruption.
234 No formal statistical sampling frame was applied; the focus was on including a wide range of lived
235 experiences of gynae-radiotherapy, regardless of time since treatment, to ensure diversity of
236 perspectives rather than statistical representativeness.

237 The study was conducted between May 2019 and September 2022. The start date refers to the
238 commencement of protocol development, and the end date marks the completion of data analysis.
239 Participant recruitment took place between August 2020 and September 2021. 35 participants were
240 consented for the contemporaneous project and narratives were received from 16 participants (one

241 participant did not submit a demographics form). There were 18 participants for the online project,
242 restricted by the time frame available to complete the project. While our approach was narrative
243 rather than semi-structured interviewing, our achieved numbers are consistent with published
244 guidance suggesting that 9–17 qualitative interviews are often sufficient for thematic saturation
245 (63). We attempted to recruit carers for the on-line project but, although some showed interest, no
246 carers consented to take part and are therefore not included in the dataset.

247 All journal entries submitted for the study were made anonymous by removing any direct identifiers
248 and using pseudonyms.

249 Participants were able to select a correspondence method from handwritten entries, voice or video
250 recordings and electronic journal methods, switching between recording approaches if they chose
251 to. For voice recordings, participants were provided with an encrypted digital recording device,
252 which they sent to the team at the end of the study. Video recordings were password protected and
253 sent via email.

254 Participants were asked to contribute narrative accounts on topics important to them in as many
255 narrative entries as they wished. Participants were asked to provide a short “about me” section to
256 identify whether they are a patient, carer or significant other and to contextualise their accounts in
257 terms of diagnosis and treatment and time since treatment. From that point, content was solely
258 directed by participants and, in line with previous research, the form, length and content varied (64).

259 ***Analysis***

260 Consistent with the feminist and participatory ethos of the study, analysis was conducted
261 collaboratively to ensure that multiple perspectives, including those of a patient researcher,
262 informed interpretation. To reduce bias in analysis, all narratives were collaboratively analysed by
263 members of the multidisciplinary research team, which included sociologists (LAA, HS, VS, MK-F),
264 Radiotherapy Practitioners (DH, LS, LAA), and a Patient Researcher recruited from the initial
265 methods workshop (CS). Video and audio narratives were transcribed verbatim prior to analysis.

266 The processes was guided by an analytical frame developed from the study aims and research
267 questions, and was used to explore:

- 268 • Practical, physical, emotional and social demands placed upon those receiving gynae-
269 radiotherapy treatment;
- 270 • Impacts on carers and significant others;
- 271 • When, how and why difficulties arise for patients;
- 272 • How demographic, cultural, and social factors shape experiences;

- 273 • How individuals mobilise official and interpersonal resources to cope with treatment;
274 • The priority concerns and/or anxieties of patients and their significant others.

275 Analysis combined a primarily deductive approach, directed by this framework, with flexibility to
276 identify new or unanticipated themes emerging from the narratives. This included adopting
277 abductive insight, in which instances that disrupted expectations or appeared surprising were
278 actively explored to generate new insights and deepen interpretation. This hybrid approach ensured
279 that the findings addressed the study objectives while remaining responsive to participants' lived
280 experiences. Initial coding categories were derived from the analytical frame, but were iteratively
281 expanded, refined, and reorganised as new patterns and meanings were identified within the data.

282 All transcripts were read in full by at least two team members. Coding was conducted collaboratively
283 rather than by independent double coding of all transcripts; pairs or small groups of researchers
284 worked together to code each transcript in detail. Throughout the analysis phase, the research team
285 held regular meetings to compare interpretations, resolve discrepancies, refine codes, and develop
286 thematic categories. These discussions formed a process of reflexive analytical dialogue, where
287 differences in interpretation were explored, in line with qualitative approaches that prioritise depth
288 and meaning over inter-coder reliability metrics. This iterative process, illustrated in Figure 1,
289 involved continual movement between coded data, the analytical frame, and original narratives to
290 preserve the richness and context of participants' experiences.

291 The findings were subsequently collated into a free to access book with seven (short) sections, each
292 led by a different member of the research team, including co-author and patient researcher (CS)
293 (65)¹. Content was developed through a collaborative writing process, including a week-long writing
294 sprint to work together on developing the book content and generate key recommendations. This
295 approach ensured that recommendations reflected both the research evidence and the experiential
296 expertise within the team. The project's steering group, comprising clinicians and researchers,
297 reviewed the draft recommendations prior to finalisation, reinforcing the applicability of the findings
298 for practice, policy and advocacy.

299 The reporting of this study conforms to the Standards for Reporting Qualitative Research (SRQR)
300 checklist ensuring comprehensive and transparent qualitative research reporting (66).

301 **Results**

¹ The book is available to order from <https://lancasteruk.estore.flywire.com/products/we-need-to-talk-aboutradiotherapy-for-gynaecological-cancer-303838>

302 The contemporaneous study collected 45 narratives from 16 women who were invited to submitted
303 narratives from the start of their treatment and up to six months after ending treatment. The online,
304 study collected a total of 33 narratives from 18 participants. All participants had received treatment
305 radiotherapy for a gynaecological cancer. The median number of narratives submitted was one and
306 the maximum submitted for one participant was five, as some participants chose to write their
307 narratives over several weeks. One participant submitted their narrative as a video and a verbatim
308 transcription was made. One narrative was submitted as an audio recording and all other narratives
309 were submitted as electronic text. Participants had all received radiotherapy for gynaecological
310 cancer up to 25 years previous. Table 1 shows the demographic details of participants. Given
311 participants identification as women, they are referred to as such in the following results section,
312 however it is recognised that not all people who receive treatment for gynaecological cancers
313 identify as women.

314 Analysis identified seven principal areas for developing conversations for support, consolidated into
315 four overarching, interconnected themes for this paper: *Living Through Treatment and Its Physical*
316 *Impacts; Shifts in Identity, Sexuality and Intimacy; Navigating Emotional and Psychological*
317 *Wellbeing; Communication, Dignity and the Practices that Support or Undermine Them*. Participant
318 quotes illustrating each theme are presented in Table 2.

319 (1) Living Through Treatment and Its Physical Impacts

320 The narratives describe many and varied demands of treatment, including emotional, physical, and
321 social challenges. Anxiety was common, for example, prior to hospital appointments, about the
322 treatment itself, about getting to and from the hospital (including parking), and about family and
323 work commitments. Many women described normalising or enduring pain and discomfort, reflecting
324 a culture of resilience in the face of treatment. Reflecting on her treatment, one woman described
325 feeling obliged to, “just get on with it,” while another rationalised her pain through comparison to
326 experiences of pre-existing health conditions.

327 Many women sought support, but when they did, they reported that professionals’ used generic
328 phrases, such as “it will get worse before it gets better”. These phrases or clichés did not fully
329 address their needs or concerns nor reflect the evolving situation. Some women felt professionals
330 selected a phrase from a ‘library’ of responses to encourage them to persevere, rather than
331 providing person-centred, tailored support. This led some women to feel that they had not been
332 heard.

333 Although the physical side effects of radiotherapy are well-documented in clinical literature, the
334 experience of late effects often came as a shock, and women were surprised by their persistence
335 and intensity. Changes to bladder and bowel continence, including leaks and urgency, disrupted
336 expectations of life post treatment and had tangible psychosocial consequences, including
337 limitations at work, social isolation, and reduced self-esteem. Many spoke about the lack of
338 recognition for their bowel and bladder issues amongst professionals, the upset it caused to family
339 and friends, and the embarrassment and humiliation they experienced. They planned their days to
340 ensure they were close to toilets, carried spare underwear, panty-liners, and water for washing,
341 avoiding public transport, and feeling extremely isolated. Some women had felt obliged to return to
342 work before they were ready, due to lack of support and understanding from employers, and due to
343 their financial situation. Some women described the difficulty of having conversations with
344 employers after treatment, requiring repeated conversations about needs such as being near a
345 toilet, having to discuss intimate subjects with managers multiple times because messages were not
346 passed on or needs unaccommodated. One participant was relieved to work from home, where she
347 could move freely and avoid a car commute.

348 The women's narratives show that the consequences of cancer treatment can be permanent and
349 impact many areas of life. This came as a shock to many of the women, as they had expected that
350 finishing treatment and recovering would mean moving on. Most follow-up appointments end five
351 years after treatment, often before late effects start. This means that late effects are rarely linked to
352 radiotherapy, and women are treated by various separate professionals. As a result, women
353 reported feeling as if they are each unique in their suffering and have nowhere to turn for validation.

354 Some radiotherapy treatments for gynaecological cancer (especially brachytherapy) can cause
355 vaginal narrowing, while surgery can shorten vaginal length. Many women described being told to
356 use dilators after treatment. Several women said that dilator use was explained in terms of enabling
357 future medical examinations. They felt this clinical perspective ignored their relationship with their
358 own body and sexual self, both physically and emotionally. Women described feeling less feminine;
359 that their vaginas had been medicalised and problematised, and some felt embarrassed. Using the
360 dilators was "far from comfortable," sometimes painful, and that they could not use the larger
361 dilators. Nevertheless, most used them despite discomfort and pain to maintain their sexual selves.
362 These physical impacts often cascaded into changes in women's identities, sexual selves, and
363 intimate relationships, which are explored in the next theme.

364 (2) Shifts in Identity, Sexuality and Intimacy

365 Several of the women described disruptions to identity and how treatment changed how they saw
366 themselves. One woman described how her humorous self conflicted with the seriousness of her
367 cancer diagnosis, and how her treatment conflicted with her identity as a professional. Others
368 described how being viewed as a “patient” was disruptive. The women’s narratives showed that
369 these disruptions can lead to feelings of guilt and anger alongside gratitude at both being able to
370 have treatment, and to family and friends for their support.

371 Making sense of these conflicting emotions was not straightforward for patients or their family and
372 friends. Many women described changes in relationships following diagnosis and treatment: some
373 grew stronger, while others struggled. Women reflected that family and friends sometimes found it
374 hard to respond appropriately. While wanting to show care, their expressed concerns could have the
375 opposite effect. For some, being able to work and having supportive managers and colleagues
376 significantly impacted their experiences. Many women described how life continues alongside the
377 disruptions. They often tried to hold on to some kind of normality while also experiencing chaos of
378 treatment and life after treatment. One woman described how difficult the daily commute and work
379 routines were, and that emotional expressions of concern were disruptive for herself and others.

380 The women’s experiences of their sexual self during and after treatment were diverse, including not
381 being sexually active, masturbation, relationships with others and with their own bodies, the loss of
382 vaginal sex and development of new intimacies, and gaps in care. Many women wanted
383 acknowledgment of their sexual selves, having found treatment “life changing in more ways than
384 one.” Some women described loss of self-confidence, feeling unattractive and “un-sexy.” Some felt
385 alienated from their bodies, experiencing loss of control and choice about their sexual self, resulting
386 from diagnosis, treatment, or premature menopause. For one participant, treatment induced
387 infertility made her feel like her body did not belong to them, negatively impacting intimacy with her
388 boyfriend and their relationship. Other women described putting their sex life on hold and sex lives
389 being “switched off” due to skin damage. However, some women found pleasure in alternatives to
390 vaginal sex and their relationships changed in some positive ways, becoming closer through
391 supporting each other.

392 Pain, and fear of pain, prevented some women from having a sexual self. For some women and their
393 partners, thoughts of sex promoted thoughts of cancer. Many wanted a sexual self and some felt
394 guilty for it. When they were able to have sex, some felt fulfilled. The commonly used language of
395 ‘vaginal vault’ and ‘stump’ made some women feel alienated from their bodies and caused a sense
396 of loss of intimacy and control over their own body. Some women reflected on the lack of
397 communication and acknowledgment treatment’s impact on sexual lives and sexual pleasure. Others

398 described the lack of opportunities to talk to their clinical team about sexual wellbeing resulting in
399 feelings that they did not have the right to speak about, or do anything about, their sexual selves.
400 Women described seeking advice elsewhere, due to the perceived embarrassment of the clinical
401 team they concluded that the medical team should not be expected to offer any guidance about sex
402 and a sexual self, even though this had been affected by her treatment. One woman suggested the
403 need for guides to having sex whilst having cancer treatment, noting most booklets focus on signs
404 that you may have cancer, or sex after treatment. Disruptions to identity and intimacy often
405 intersected with emotional wellbeing, sometimes amplifying distress or shaping coping strategies, as
406 discussed in the next theme.

407 (3) Navigating Emotional and Psychological Wellbeing

408 Many women described fear and worry as a part of having treatment. For some women, these
409 feelings eased, while for others they lingered for months or years after ending treatment. Women
410 had different emotional responses to treatment and varied ways of living with the treatment in the
411 short and long term. Their narratives show that what is right for one person was not necessarily right
412 for another, and what works now may not work later. Many of the women highlighted that having
413 conversations about mental health is important, not only with healthcare professionals, but also
414 with family and friends. Though family and friends may struggle to fully understand, these
415 conversations helped them feel understood and supported.

416 Many of the women had felt obliged to be “strong” and “just put up with it,” which was difficult for
417 mental health. They described feeling angry that life would never be the same again and frustration
418 that others did not understand that the treatment being “over” did not mean everything was back to
419 normal.

420 Some narratives disclosed feelings of trauma, including both explicit and implicit comparisons
421 between brachytherapy and rape or sexual trauma. The distress of the women in these narratives
422 was clearly articulated and whilst these may not be universal experiences of radiotherapy, their
423 narratives provide opportunities to reflect on how radiotherapy could become ‘trauma informed.’
424 One woman, who had an oncology nursing background, wrote very strongly on the adaptations that
425 could be made to brachytherapy to reduce feelings of vulnerability describing the experience of
426 brachytherapy as being “impaled on a radioactive dildo”. After treatment completed, she reported
427 feeling very emotional, tearful, and shaken by her experience, and that she would have welcomed a
428 follow up chat from staff to check on her emotional wellbeing. Unfortunately, she reported that staff
429 were only concerned with treatment side effects. While awareness of brachytherapy’s potential
430 trauma exists, knowing how to prepare and respond to these patients requires further work. How

431 these emotional and psychological experiences were acknowledged—or overlooked—by
432 professionals was closely tied to communication, dignity, and support systems, explored in the final
433 theme.

434 (4) Communication, Dignity and Practices That Support or Undermine 435 Them

436 Some women expressed dissatisfaction with the consent process. Their narratives suggested that
437 fully informed consent requires ongoing conversations that consider individual priorities, including
438 the weight individuals may attach to different outcomes, and how that may change when
439 considering the permanency of late effects.

440 The women’s narratives revealed subtle lapses in care that undermined dignity, a fundamental
441 human right. The Radiographers’ Code of Conduct and Ethics stresses respecting individual dignity,
442 to prevent behaviour that causes physical, emotional, or psychological distress or damage to
443 anyone. Yet women regularly described micro-infringements of their dignity, ranging from forgetful
444 moments, mundane practices, intentional and unintentional incidents. Such lapses are sometimes
445 presented as inevitable or embedded into structures and routines of care. As a nurse, one
446 participant reflected on her own experience of giving care. She talked of a lack of control after
447 brachytherapy and said that “small things” could have been done to support her. Women often
448 presented neglect of “small things” such as their warmth, comfort, adequate covering of their body,
449 that represent micro-infringements that cumulatively impacted their sense of dignity.

450 Within their experience of chaos and unpredictability of treatment, women described how their
451 bodies were managed industrially or ‘processed’. Women described feeling like they were on a
452 conveyor belt, where service efficiency overshadowed individual experience. This industrial
453 approach masked systemic problems, such as appointment times and transport, and hindered open
454 discussion about issues such as dealing with treatment effects or changes in sexual wellbeing.
455 Women also reported a lack of control over appointment changes or treatment delays, which
456 threatened plans and routines and led to feelings of disrespect. Despite the challenges, women
457 talked about activities they did to maintain some control: healthy eating, exercise, breathing,
458 relaxation, and afternoon snoozes. These wellbeing promoting techniques are often recommended
459 and many of the women described how helpful they were.

460 Communication played a crucial role in experiences of dignity and control. The women’s experiences
461 emphasised that getting the right information, at the right time, in the right way, influenced how
462 information is processed and responded to. Many women first received NHS or Macmillan leaflets,

463 which some found helpful, while others felt they were too general and did not meet their needs.
464 Leaflets were sometimes given in response to questions deemed irrelevant by clinical staff, or
465 considered to fall outside of treatment appointments, leaving gaps in information that caused
466 anxiety and a sense of being uninformed. However, an issue that spanned many narratives was how
467 much information was the 'right' amount. Some thought it was better not to know, while others
468 wished for more accurate information. Many women also felt they were not "taking it all in" and
469 potentially blamed themselves for not processing what they had been told. There was a difference
470 between knowing about radiotherapy and acute/late effects abstractly and believing they would
471 personally develop them.

472 Many women reported poor communication about concerns, harming trust between patients and
473 practitioners. Some were told not to worry, or felt their concerns were dismissed and described an
474 absence of empathetic and sincere communication and compassion in clinical encounters. Well-
475 meaning loved ones and practitioners sometimes downplayed worries with phrases like "be brave"
476 or "grin and bear it." These phrases, though well-meaning, could stifle communication and dismiss
477 significant feelings and experiences. One women suspected she had insufficiency fractures, but
478 these were initially dismissed as these were not visible on an X-ray. She also described suffering
479 bladder and bowel inflammation and incontinence, her consultant responded dismissively, "You can
480 always wear incontinence pads, can't you? Well, you've had radiotherapy, what do you expect??"
481 Such dismissals undermined trust and confidence in clinical teams. Overall, these narratives highlight
482 that dignity, control, and effective communication are closely connected. Structural pressures and
483 routine care practices sometimes challenged women's autonomy and sense of self, but women's
484 strategies to maintain control demonstrate their resilience and the importance of person-centred,
485 empathetic communication.

486 From Findings to Action

487 The accounts point to systemic gaps in communication, respect, and recognition of patients' lived
488 realities. Responding to them demands clear, patient-driven commitments. Drawing directly from
489 participants' accounts, these commitments were distilled into the "Manifesto for Change," printed
490 on the back cover of the project book. The manifesto sets out practical, values-based demands to
491 guide radiotherapy services and ensure the best possible experience for all.

- 492 1. Practice radiotherapy as an on-going conversation between patients and practitioners.
493 Solicit and invite patients' questions: view every question as important and requiring an
494 answer (not just a leaflet).

- 495 2. Acknowledge that every patient trajectory is unique: non-linear, emotional, social, intimate
496 and physical. It begins before diagnosis and extends beyond treatment.
- 497 3. Prioritise what the patient is feeling and experiencing over the goals of the treatment.
- 498 4. Begin every interaction by appreciating that illness and treatment disrupts patients' lives in
499 countless ways.
- 500 5. Give space and time for each patient to be upset and feel heard, and value their particular
501 experiences.
- 502 6. Demand services that promote and prioritise dignity.
- 503 7. Remember that attending to the sexual self is part of caring for and treating gynaecological
504 cancer.
- 505 8. Demand acknowledgment of and care for late effects.
- 506 9. Avoid language that unnecessarily medicalises parts of the body.
- 507 10. Demand equal patient access to all services.
- 508 11. Given the disclosures made by participants which were distressing and indicative of trauma,
509 we recommend a consideration of how delivery of radiotherapy services may become
510 trauma-informed.

511 **Discussion**

512 This research sought to explore the multifaceted social, personal, and sexual consequences of gynae-
513 radiotherapy, offering the first detailed patient-narrative account focused specifically on this
514 treatment. By adopting a feminist, narrative approach, the study centred patient voices to
515 understand how radiotherapy intersects with identity, agency, and everyday life, highlighting
516 structural and cultural influences on experience while informing the development of holistic,
517 patient-centred supportive care.

518 Findings reinforce that, despite advances in radiotherapy technology, patients' experiences of sexual
519 wellbeing, emotional support, and social concerns remain insufficiently addressed. Technical
520 precision has not automatically translated into holistic support, leaving persistent gaps in
521 communication, attention to lived experience, and individualised care. The four identified themes
522 reflect overlapping and mutually influencing dimensions of the radiotherapy experience. Physical
523 impacts shaped identity and emotional wellbeing, while communication influenced experiences of
524 dignity and support. Trauma permeated emotional, physical, and relational domains. For example,
525 bladder incontinence (Theme 1) undermined sexual confidence (Theme 2), contributed to feelings of
526 isolation and low mood (Theme 3), and was often minimised by professionals (Theme 4). This
527 integrated thematic framework provides an understanding of women's lived experiences and

528 highlights areas where systemic, cultural, and policy change is needed to improve holistic, patient-
529 centred care.

530 The physical, sexual, and psychosocial effects of gynaecological radiotherapy are well documented
531 (14,41,42,67,68), yet the persistence of medicalised descriptions of effects has not engendered a
532 change in practice. Participants in the present study described feeling unsupported, unheard, and
533 unable to address concerns about intimate, emotional, and social impacts of radiotherapy treatment
534 for gynaecological cancer. Participants frequently reported not being listened to or not being heard
535 or their experience was portrayed as ‘necessary suffering,’ or feeling abandoned post-treatment,
536 which chimes with other research findings (10,11,69,70).

537 Our study extends this literature by showing how ‘enforced positivity’ shapes patient behaviour and
538 the care they receive. Encouragement to adopt positive thinking, including concepts such as
539 “posttraumatic growth” and “teachable moments” (71), can generate pressure for patients to
540 present a publicly positive persona. This was evident in the narratives collected, where women
541 undergoing radiotherapy for gynaecological cancers felt unable to express distress or concerns about
542 intimate and physical impacts of treatment. While well-intentioned, such expectations can minimise
543 suffering and silence distress, as also critiqued historically in breast-cancer literature (47).

544 Symbolic cancer awareness campaigns, such as coloured ribbons for ovarian, cervical and other
545 cancers, and survivorship narratives, what Segal has termed ‘cancer triumphalism,’ (72) can obscure
546 real distress, reinforce invisibility and normalise care that infringes dignity or ignores lived
547 experience. Cultural pressures have practical effects, silencing negative accounts and encouraging
548 patients to accept pain and suffering, as revealed in the findings of the present study. Such
549 narratives maintain myths that undermine the lived experience of living with and beyond cancer.
550 Accounts of triumph over adversity, ‘making it through’ against the odds and validating
551 achievements, could influence societal expectations of behaviour and set up feelings of inadequacy
552 for those who do not feel as positive, or who are positioned differently in society and face diverse
553 and intersecting external and/or structural demands. Moreover, such accounts can make it difficult
554 for patients to have open conversations, especially conversations that include pain, distress,
555 damage, and long-term effects.

556 The findings of this study demonstrate the importance of initiating and sustaining meaningful
557 conversations about radiotherapy treatment and its diverse effects. The findings revealed that
558 conversations can be difficult to initiate or are easily closed down and yet many issues could be
559 resolved through careful conversations. A subsequent study by our team further explored these
560 issues, focusing on enhancing practitioners' ability to engage in meaningful conversations about

561 sexual wellness and pleasure with patients undergoing radiotherapy for gynaecological cancers (73),
562 highlighting a pathway to practice improvement.

563 The move by the UK Royal College of Radiologists to introduce standardised radiotherapy consent
564 forms has ensured the content of consent conversations has been given attention, enabling a move
565 towards standardisation of information provided as part of informed consent (74,75). Yet, focussing
566 consent on completing a medicalised form further highlights the tendency of providers to discuss
567 treatment in medical and generalised terms. Without systemic change to support patient-centred
568 consent and shared decision-making, completing the form may take precedence over the small,
569 meaningful conversations, further drowning out concerns that matter most to patients.

570 **Reflexivity and Researcher Positionality**

571 The study was informed by a feminist epistemological approach that recognises knowledge as
572 situated and shaped by researchers' social, professional, and embodied positions. Several members
573 of the team had personal or professional experience of cancer care. The patient researcher (CS), who
574 had lived experience of gynaecological cancer and radiotherapy, contributed throughout the study,
575 including the co-design workshop, development of study materials, data interpretation, and
576 refinement of themes. Her experiential knowledge was central in ensuring that the analysis
577 remained grounded in patient priorities and in identifying issues that may otherwise have been
578 overlooked, particularly around late effects, sexuality, and everyday impacts of treatment.

579 Clinical members of the team reflected on how engagement with the narratives challenged taken-
580 for-granted practices within radiotherapy, including the use of standardised language, time-
581 pressured interactions, and limited discussion of sexual wellbeing. This prompted critical reflection
582 on their own professional roles and assumptions, particularly where care practices may
583 unintentionally silence or minimise patient experiences.

584 Researchers from social science backgrounds brought a feminist and critical lens to the analysis,
585 attending to issues of power, voice, and the marginalisation of embodied knowledge within
586 biomedical contexts. For some team members, personal experiences of cancer (albeit different
587 diagnoses) shaped empathetic engagement with the data, while also requiring reflexive awareness
588 to avoid over-identification with participants' accounts.

589 Reflexivity was embedded throughout the analytic process via collaborative coding, regular team
590 discussions, and the inclusion of a patient researcher in interpretive decision-making. This iterative
591 approach enabled the team to critically examine how their perspectives shaped data interpretation,

592 while prioritising participants' narratives as the primary source of insight. Each member of the
593 research team wrote a personal reflection which was included in the co-authored book (65).

594 **Strengths**

595 This study offers one of the most detailed qualitative examinations of the social, personal, and
596 sexual impacts of gynaecological radiotherapy to date. Using a feminist methodological approach,
597 the research was co-produced with stakeholders, including patients, patient representatives, and
598 members of a project steering group, ensuring that the voices of those most affected shaped every
599 stage. Collaboration with clinical teams ensured that the insights generated were not only authentic
600 to lived experience but also directly translatable into actionable changes in practice. This integration
601 of experiential expertise, clinical knowledge, and feminist critique produced findings that go beyond
602 description, providing a foundation for activist research that demands transformation in policies,
603 practices, and systems that affect patient wellbeing, principles that underpin the manifesto for
604 change.

605 **Limitations**

606 The lack of demographic diversity is a clear limitation. Despite targeted outreach through charities
607 specialising in LGBTQI+ cancer experience, all participants identified as white, heterosexual women.
608 Perspectives from sexual minorities, non-binary individuals, ethnically diverse groups and those with
609 varied socioeconomic, disability, and age profiles are therefore absent. This demographic
610 homogeneity is reflected in the limited discussion of sexual pleasure beyond heterosexual
611 experiences, producing silences that are important to acknowledge. Such silences reflect broader
612 politics of research exclusion, connected to the silencing of traumatic or shameful experiences,
613 compounded by intersecting exclusions via ableism, racism and cis-heteronormativity (76–79).

614 Recruitment was further constrained by the COVID-19 pandemic, which limited face-to-face
615 recruitment opportunities but also intensified barriers for underrepresented groups, many of whom
616 faced heightened health vulnerabilities, digital exclusion, and competing priorities during this period.
617 These factors compounded existing systemic challenges in engaging marginalized populations within
618 health research.

619 Participants in the on-line study self-selected by contacting the research team, which may mean
620 those with more significant issues were more motivated to participate, potentially shaping the
621 emphasis and intensity of experiences reported. Shifting the study design due to the impacts of
622 COVID-19 enabled more insight into longer term effects of treatment and revealed experiences as
623 remembered by participants. However, the original aim of the research, to gather contemporaneous

624 accounts, was not realised in accounts submitted as part of the second study. The temporal
625 heterogeneity adds strength to the data set showing how participants reflect on their experiences of
626 treatment. Their recall of treatment provides important considerations for consent and experiences
627 of care. In the context of this study, how people look back on treatment became more important
628 than how accurate their retelling of care was. We did not specifically examine whether time since
629 treatment influenced the nature or frequency of concerns raised, as the study was not designed or
630 powered to make such comparisons. While some participants reflected on changes in their
631 experiences over time, these were not analysed systematically.

632 Narratives were submitted in multiple formats (written, audio, and video), which may have
633 influenced the depth, style, and content of accounts, although all were transcribed and analysed
634 consistently. The use of multiple data collection modalities supported more inclusive participation
635 and enabled participants to express their experiences in ways that suited them.

636 Future research should adopt more proactive, culturally sensitive, and community-engaged
637 recruitment strategies, including building trusted partnerships with diverse communities and
638 leveraging multiple outreach modalities.

639 **Conclusion**

640 Informed by a feminist approach, the project aimed to increase understanding of how gynae-
641 radiotherapy impacts on social, personal, and sexual lives, and to improve patient experiences of
642 living with the social and personal impacts of radiotherapy. Building on a tradition of feminist health
643 activism, it treated patient experience as a vital form of expertise and reframed care as more than
644 the delivery of treatment, something to be shaped, questioned, and improved through active
645 participation in service design and decision making. Through the collection of patient narratives, it
646 was found that radiotherapy creates often silenced burdens on patients. In taking a feminist
647 approach to understanding experience, the study attended to social and emotional aspects of gynae-
648 radiotherapy alongside biological. The project findings were not wholly positive, and it was
649 important to reject the pressure to cleanse and downplay the distress of treatment for a
650 gynaecological cancer when presenting the narratives. Playing down private suffering and presenting
651 a positive public image, often to protect loved ones and not alienate support or jeopardise care,
652 ignores the lived realities of cancer. This act of 'censoring accounts' is done to prioritise other
653 people's comfort and can create a burden of emotional work for a cancer patient.

654 The study demonstrates the importance of embedding patient voices and experiential knowledge
655 into the design and delivery of radiotherapy services. For research, it highlights the need for

656 inclusive studies exploring the intersection of gynaecological cancer, sexuality, and emotional
657 wellbeing, with a focus on underrepresented groups. For policy, the findings support integrating
658 trauma-informed, dignity-centred care principles into national radiotherapy guidelines and
659 commissioning frameworks. For practice, the Manifesto for Change offers a patient-driven agenda
660 that can be used to train staff, inform service development, and guide meaningful conversations
661 with patients before, during, and after treatment. By translating lived experience into actionable
662 recommendations, the project exemplifies how patient-led insights can create an agenda for
663 transformative change across practice and policy.

664 **List of Abbreviations**

665 CET Clinical Effectiveness Team

666 **Statements and Declarations**

667 Acknowledgements

668 We are extremely grateful to all the women who shared their experiences with us. Our fundamental
669 concern has been to treat these narratives with respect and care, ensuring we learn from them to
670 improve care practices and experiences of those undergoing radiotherapy for a gynaecological
671 cancer.

672 We also thank the attendees of the co-design workshop, whose insights helped shape the study's
673 methods, and the members of the project steering committee for their expertise and guidance
674 throughout. Special thanks go to Lynda Appleton, Charlotte Baugh and Hannah Doughty, who
675 worked with us to recruit participants and provided valuable feedback in team meetings.

676 Author Contributions

677 This study was designed by LA, VS, HS, MKF, DH and CS. MKF and LS were responsible for participant
678 recruitment for the contemporaneous study. HS was responsible for participant recruitment for the
679 on-line study. Data analysis was carried out by all authors. LA wrote the first draft of the manuscript,
680 VS, HS, MKF, DH, and CS contributed sections and provided comments. VS, HS, MKF, DH, LS and CS
681 approved the final manuscript.

682 Ethics Approval and consent to participate

683 This study was performed in accordance with the Declaration of Helsinki and approved by the East of
684 Scotland Research Ethics Committee (20/ES/0008) and Lancaster University Faculty of Health and
685 Medicine Research Ethics Committee (FHMREC19086).

686 Written informed consent was obtained from all the subjects involved in the study.

687 Consent for Publication

688 Written informed consent included consent for publication of anonymised data.

689 Declaration of Conflicting Interest

690 The authors declared no potential conflicts of interest with respect to the research, authorship,
691 and/or publication of this article.

692 Funding Statement

693 The research was funded by North West Cancer Research CR1201.

694 Data Availability

695 The datasets generated and analysed during the current study are not publicly available due
696 potentially identifiable participant and organisation information through the narratives but are
697 available from the corresponding author on reasonable request.

698

699 **References**

- 700 1. Woolnough S. Cancer in women - addressing unmet needs [Internet]. British Medical Association;
701 2018 [cited 2025 Dec 8]. Report No. Available from: [https://www.bma.org.uk/media/2112/bma-](https://www.bma.org.uk/media/2112/bma-womens-health-cancer-in-women-aug-2018.pdf)
702 [womens-health-cancer-in-women-aug-2018.pdf](https://www.bma.org.uk/media/2112/bma-womens-health-cancer-in-women-aug-2018.pdf)
- 703 2. NDRS [Internet]. [cited 2025 Aug 12]. CS2 - An introduction to the reporting platform. Available
704 from: <https://digital.nhs.uk/ndrs/data/cancerstats2-platform-user-guide>
- 705 3. Cancer Research UK,. Cancer Research UK [Internet]. [cited 2025 Aug 12]. Cancer Statistics for the
706 UK. Available from: [https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-](https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk)
707 [the-uk](https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk)
- 708 4. Sekse RJT, Hufthammer KO, Vika ME. Fatigue and quality of life in women treated for various
709 types of gynaecological cancers: a cross-sectional study. *Journal of clinical nursing*. 2015;24(3–
710 4):546–55.
- 711 5. Pfaendler KS, Wenzel L, Mechanic MB, Penner KR. Cervical cancer survivorship: long-term quality
712 of life and social support. *Clinical therapeutics*. 2015;37(1):39–48.
- 713 6. Hofsjö A, Bergmark K, Blomgren B, Jahren H, Bohm-Starke N. Radiotherapy for cervical cancer -
714 impact on the vaginal epithelium and sexual function. *Acta Oncol*. 2018 Mar;57(3):338–45.
715 doi:10.1080/0284186X.2017.1400684 PubMed PMID: 29140150.
- 716 7. Baumann BC, Zeng C, Freedman GM, Verginadis II, MacArthur KM, Lin LL, et al. Avoiding
717 antiperspirants during breast radiation therapy: Myth or sound advice? *Radiotherapy and*
718 *Oncology*. 2017;124(2):204–7.
- 719 8. Schnur JB, Ouellette SC, Bovbjerg DH, Montgomery GH. Breast cancer patients' experience of
720 external-beam radiotherapy. *Qualitative health research*. 2009;19(5):668–76.
- 721 9. Larsson M, Hedelin B, Athlin E. Needing a hand to hold: Lived experiences during the trajectory of
722 care for patients with head and neck cancer treated with radiotherapy. *Cancer Nursing*.
723 2007;30(4):324–34.
- 724 10. Sidenius A, Mogensen O, Rudnicki M, Møller LMA, Hansen HP. Feeling lucky: hierarchies of
725 suffering and stories of endometrial cancer in a Danish context. *Sociology of Health & Illness*.
726 2019;41(5):950–64. doi:10.1111/1467-9566.12875
- 727 11. Stewart H, Ashmore L, Kragh-Furbo M, Singleton V, Hutton D. Ghosts in the machinery:
728 Living with and beyond radiotherapy treatment for gynaecological cancer. *Health*. 2024;28(1):90–
729 107.
- 730 12. Fang P, Tan KS, Grover S, McFadien MK, Troxel AB, Lin L. Psychosocial encounters correlates
731 with higher patient-reported functional quality of life in gynecological cancer patients receiving
732 radiotherapy. *Radiation oncology*. 2015;10(1):34.
- 733 13. Adams E, Boulton M, Horne A, Rose P, Durrant L, Collingwood M, et al. The effects of pelvic
734 radiotherapy on cancer survivors: symptom profile, psychological morbidity and quality of life.
735 *Clinical Oncology*. 2014;26(1):10–7.
- 736 14. Lind H, Waldenström AC, Dunberger G, al-Abany M, Alevronta E, Johansson KA, et al. Late
737 symptoms in long-term gynaecological cancer survivors after radiation therapy: a population-

- 738 based cohort study. *Br J Cancer*. 2011 Sep 6;105(6):737–45. doi:10.1038/bjc.2011.315 PubMed
739 PMID: 21847122; PubMed Central PMCID: PMC3171018.
- 740 15. Ludlow H, Green J. Gastrointestinal symptoms of pelvic radiation disease (part 1): literature
741 review. *Gastrointestinal Nursing*. 2020 Mar 2;18(2):40–5. doi:10.12968/gasn.2020.18.2.40
- 742 16. Fairweather D, Taylor RM, Allington L, Haji N, Fersht N, Chang YC, et al. Do Patient-Reported
743 Outcome Measures (PROMs) Used Within Radiotherapy Clinical Trials Reflect the Impact of
744 Treatment? *Cancers (Basel)*. 2024 Nov 14;16(22):3832. doi:10.3390/cancers16223832 PubMed
745 PMID: 39594787; PubMed Central PMCID: PMC11592418.
- 746 17. Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, et al. Impact of cancer-
747 related fatigue on the lives of patients: new findings from the Fatigue Coalition. *The oncologist*.
748 2000;5(5):353–60.
- 749 18. Stone PC, Minton O. Cancer-related fatigue. *European journal of cancer*. 2008;44(8):1097–
750 104.
- 751 19. Bodurka DC, Sun CC. Sexual function after gynecologic cancer. *Obstetrics and Gynecology*
752 *Clinics*. 2006;33(4):621–30.
- 753 20. Merchant S, O'Connor M, Halkett G. Time, space and technology in radiotherapy
754 departments: how do these factors impact on patients' experiences of radiotherapy? *European*
755 *journal of cancer care*. 2017;26(2).
- 756 21. Vermeer WM, Bakker RM, Stiggelbout AM, Creutzberg CL, Kenter GG, Ter Kuile MM.
757 Psychosexual support for gynecological cancer survivors: professionals' current practices and
758 need for assistance. *Supportive Care in Cancer*. 2015;23:831–9.
- 759 22. Malterud K, Candib L, Code L. Responsible and responsive knowing in medical diagnosis: the
760 medical gaze revisited. *NORA - Nordic Journal of Feminist and Gender Research*. 2004
761 Apr;12(1):8–19. doi:10.1080/08038740410005712
- 762 23. Ussher JM, Perz J, Gilbert E, Wong WT, Mason C, Hobbs K, et al. Talking about sex after
763 cancer: a discourse analytic study of health care professional accounts of sexual communication
764 with patients. *Psychology & health*. 2013;28(12):1370–90.
- 765 24. Hyde A. The politics of heterosexuality—a missing discourse in cancer nursing literature on
766 sexuality: A discussion paper. *International Journal of Nursing Studies*. 2007;44(2):315–25.
- 767 25. Wood L. Conceptualising decadent technology: a case study of path dependence in
768 radiotherapy. *Science as Culture*. 2015;24(4):507–25.
- 769 26. Fricker M. *Epistemic injustice: Power and the ethics of knowing*. Oxford University Press;
770 2007.
- 771 27. Wood LA. Con-forming bodies: the interplay of machines and bodies and the implications of
772 agency in medical imaging. *Sociology of Health & Illness*. 2016;38(5):768–81.
- 773 28. Shakespeare T. *Disability rights and wrongs*. Routledge; 2006.

- 774 29. Julka-Anderson N. Structural racism in radiation induced skin reaction toxicity scoring.
775 *Journal of Medical Imaging and Radiation Sciences*. 2023 Dec 1;54(4, Supplement):S44–8.
776 doi:10.1016/j.jmir.2023.09.021
- 777 30. Reeve J, Lloyd-Williams M, Payne S, Dowrick C. Revisiting biographical disruption: exploring
778 individual embodied illness experience in people with terminal cancer. *Health*: 2010;14(2):178–
779 95.
- 780 31. Trusson D, Pilnick A, Roy S. A new normal?: Women’s experiences of biographical disruption
781 and liminality following treatment for early stage breast cancer. *Social Science & Medicine*. 2016
782 Feb;151:121–9. doi:10.1016/j.socscimed.2016.01.011
- 783 32. Kenne Sarenmalm E, Thorén-Jönsson AL, Gaston-Johansson F, Öhlén J. Making sense of living
784 under the shadow of death: Adjusting to a recurrent breast cancer illness. *Qualitative health*
785 *research*. 2009;19(8):1116–30.
- 786 33. Röing M, Hirsch JM, Holmström I, Schuster M. Making new meanings of being in the world
787 after treatment for oral cancer. *Qualitative Health Research*. 2009;19(8):1076–86.
- 788 34. Moffatt S, Noble E. Work or welfare after cancer? Explorations of identity and stigma.
789 *Sociology of health & illness*. 2015;37(8):1191–205.
- 790 35. Solbrække KN, Lorem G. Breast-cancer-isation explored: Social experiences of gynaecological
791 cancer in a Norwegian context. *Sociology of Health & Illness*. 2016;38(8):1258–71.
- 792 36. Trusson D, Pilnick A. Between stigma and pink positivity: women’s perceptions of social
793 interactions during and after breast cancer treatment. *Sociology of Health & Illness*.
794 2017;39(3):458–73.
- 795 37. Quincey K, Williamson I, Winstanley S. ‘Marginalised malignancies’: A qualitative synthesis of
796 men’s accounts of living with breast cancer. *Social Science & Medicine*. 2016;149:17–25.
- 797 38. Arman M, Rehnsfeldt A, Lindholm L, Hamrin E. The face of suffering among women with
798 breast cancer—being in a field of forces. *Cancer nursing*. 2002;25(2):96–103.
- 799 39. Edbrooke L, Khaw P, Freimund A, Carpenter D, McNally O, Joubert L, et al. ENhAncing
800 Lifestyle Behaviors in Endometrial CancEr (ENABLE): A Pilot Randomized Controlled Trial. *Integr*
801 *Cancer Ther*. 2022;21:15347354211069885. doi:10.1177/15347354211069885 PubMed PMID:
802 35045735; PubMed Central PMCID: PMC8785429.
- 803 40. McGladrigan E, Wrench E, Dean E, O’Neil A, Ashmore L, Gaffney C. Exploring prehabilitation
804 interventions for patients with gynaecological cancer undergoing radiotherapy: A scoping review.
805 *PLOS ONE*. 2025 Mar 13;20(3):e0319518. doi:10.1371/journal.pone.0319518
- 806 41. Humphrey P, Dures E, Hoskin P, Cramp F. Patient Experiences of Brachytherapy for Locally
807 Advanced Cervical Cancer: Hearing the Patient Voice Through Qualitative Interviews.
808 *International Journal of Radiation Oncology*Biophysics*Physics*. 2024 Jul 1;119(3):902–11.
809 doi:10.1016/j.ijrobp.2023.12.016
- 810 42. Biran A, Dobson C, Rees C, Brooks-Pearson R, Cunliffe A, Durrant L, et al. From pelvic
811 radiation to social isolation: a qualitative study of survivors’ experiences of chronic bowel
812 symptoms after pelvic radiotherapy. *J Cancer Surviv*. 2025 Jun 1;19(3):1019–27.
813 doi:10.1007/s11764-023-01527-6

- 814 43. Tuana N. The Speculum of Ignorance: The Women's Health Movement and Epistemologies
815 of Ignorance. *Hypatia*. 2006 ed;21(3):1–19. doi:10.1111/j.1527-2001.2006.tb01110.x
- 816 44. Dreifus C. eweb:17739 [Internet]. 1977 [cited 2021 Apr 15]. Seizing Our Bodies: The Politics
817 of Women's Health. Available from:
818 <https://repository.library.georgetown.edu/handle/10822/775526>
- 819 45. Nelson J. More Than Medicine: A History of the Feminist Women's Health Movement
820 [Internet]. NYU Press; 2015 [cited 2021 Apr 15]. Available from:
821 <https://www.jstor.org/stable/j.ctt15r3z67>
- 822 46. Lorde A. *The Cancer Journals*. San Francisco: Aunt Lute Books; 1980.
- 823 47. Ehrenreich B. *Smile or die: How positive thinking fooled America and the world*. Granta
824 books; 2010.
- 825 48. King S. *Pink Ribbons, Inc: Breast cancer and the politics of philanthropy*. U of Minnesota
826 Press; 2006.
- 827 49. Jain SL. *Malignant: How cancer becomes us*. University of California Press; 2013.
- 828 50. Sulik GA. *Pink ribbon blues: How breast cancer culture undermines women's health*. Oxford
829 University Press; 2010.
- 830 51. Holmes MS. Pink ribbons and public private parts: On not imagining ovarian cancer.
831 *Literature and Medicine*. 2006;25(2):475–501.
- 832 52. Lindén L. Initiators, Controllers, and Influencers. *Healthcare Activism: Markets, Morals, and
833 the Collective Good*. 2021;140.
- 834 53. Jasen P. From the "silent killer" to the "whispering disease": ovarian cancer and the uses of
835 metaphor. *Medical History*. 2009;53(4):489–512.
- 836 54. Duff C. On the role of affect and practice in the production of place. *Environment and
837 Planning: Society and Space*. 2010;28:881–95.
- 838 55. Thomas C. *Sociologies of Disability and Illness*. Basingstoke: Palgrave Macmillan; 2007.
- 839 56. Kleinman A. *The illness narratives: Suffering, healing, and the human condition*. Basic books;
840 1988.
- 841 57. Birch M. *Reconstructing research narratives: Self and sociological identity in alternative
842 settings*. 1998.
- 843 58. Ellingson LL, Buzzanell PM. Listening to women's narratives of breast cancer treatment: A
844 feminist approach to patient satisfaction with physician-patient communication. *Health
845 Communication*. 1999;11(2):153–83.
- 846 59. Cepeda MS, Chapman CR, Miranda N, Sanchez R, Rodriguez CH, Restrepo AE, et al.
847 Emotional disclosure through patient narrative may improve pain and well-being: results of a
848 randomized controlled trial in patients with cancer pain. *Journal of pain and symptom
849 management*. 2008;35(6):623–31.

- 850 60. Hedestig O, Sandman PO, Tomic R, Widmark A. Living after radical prostatectomy for
851 localized prostate cancer. A qualitative analysis of patient narratives. *Acta Oncologica*.
852 2005;44(7):679–86.
- 853 61. Frank AW. The standpoint of storyteller. *Qualitative health research*. 2000;10(3):354–65.
- 854 62. Vaughn LM, Jacquez F. Participatory research methods—choice points in the research
855 process. *Journal of Participatory Research Methods*. 2020;1(1).
- 856 63. Hennink M, Kaiser BN. Sample sizes for saturation in qualitative research: A systematic
857 review of empirical tests. *Social Science & Medicine*. 2022 Jan 1;292:114523.
858 doi:10.1016/j.socscimed.2021.114523
- 859 64. Thomas C. Cancer narratives and methodological uncertainties. *Qualitative Research*, 8(3),
860 pp. 423-433. *Qualitative Research*. 2008;8(3):423–33.
- 861 65. Ashmore L, Singleton V, Kragh-Furbo M, Stewart H, Hutton D, Singleton C, et al. We need to
862 talk about... radiotherapy for gynaecological cancer. Lancaster, UK: Lancaster University; 2022.
- 863 66. O’Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative
864 research: a synthesis of recommendations. *Acad Med*. 2014 Sep;89(9):1245–51.
865 doi:10.1097/ACM.0000000000000388 PubMed PMID: 24979285.
- 866 67. Jensen PT, Groenvold M, Klee MC, Thranov I, Petersen MA, Machin D. Longitudinal study of
867 sexual function and vaginal changes after radiotherapy for cervical cancer. *International Journal of Radiation
868 Oncology* Biology* Physics*. 2003;56(4):937–49.
- 869 68. Smet S, Spampinato S, Pötter R, Jürgenliemk-Schulz IM, Nout RA, Chargari C, et al. Risk
870 Factors for Late Persistent Fatigue After Chemoradiotherapy in Patients With Locally Advanced
871 Cervical Cancer: An Analysis From the EMBRACE-I Study. *International Journal of Radiation
872 Oncology* Biology* Physics*. 2022 Apr 1;112(5):1177–89. doi:10.1016/j.ijrobp.2021.11.022
- 873 69. Kragh-Furbo M, Hutton D, Stewart H, Singleton V, Ashmore L. The ambivalence of
874 radiotherapy: Re-framing effects and their temporalities in treatment for gynaecological cancer.
875 *Social Science & Medicine*. 2023;336:116183.
- 876 70. Powlesland C, MacGregor F, Swainston K. Women’s experiences of information, education
877 and support when undergoing pelvic radiotherapy for gynaecological cancer: An exploratory
878 qualitative study. *Radiography*. 2023;29(1):70–5.
- 879 71. Bell K. Remaking the Self: Trauma, Teachable Moments, and the Biopolitics of Cancer
880 Survivorship. *Cult Med Psychiatry*. 2012 Dec 1;36(4):584–600. doi:10.1007/s11013-012-9276-9
- 881 72. Segal JZ. Cancer experience and its narration: An accidental study. *Literature and Medicine*.
882 2012;30(2):292–318.
- 883 73. Ashmore LA, Eastham R, Hadley O, Hanbury A, Singleton V. Supporting practitioners to talk
884 about sexual wellness and pleasure during radiotherapy for gynaecological cancer. *Radiography
885 (Lond)*. 2024 Aug;30(5):1411–7. doi:10.1016/j.radi.2024.06.012 PubMed PMID: 38944580.
- 886 74. Royal College of Radiologists. National standard site-specific radiotherapy consent forms.
887 London, UK; 2021. p. 13. Report No.

- 888 75. Kenney-Herbert E, Mylonas M, Todd J, Tipples K. Consent consensus: time for a national site-
889 specific consent form for radiotherapy? *Clinical Oncology*. 2021;33(1):1–4.
- 890 76. Jones C, Cheuk F. Something is happening: Encountering silence in disability research.
891 *Qualitative Research Journal*. 2021;21(1):1–14.
- 892 77. Dhawan N, LeBlanc TW. Lean Into the Uncomfortable: Using Trauma-Informed Care to
893 Engage in Shared Decision-Making With Racial Minorities With Hematologic Malignancies. *Am J*
894 *Hosp Palliat Care*. 2022 Jan;39(1):4–8. doi:10.1177/10499091211008431
- 895 78. Mazur SL, Sharma JB. Medical Oversight and Public Trust of Medicine: Breaches of Trust. In:
896 McFarland DC, Grassi L, Silver SM, Riba MB, editors. *The Complex Role of Patient Trust in*
897 *Oncology*. Springer International Publishing; 2024. p. 35–55.
- 898 79. Brossard B. *The Sociology of Trauma*. Forthcoming.
- 899